{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:19:08.687486",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 37,
    "temperature": 0.1
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial embolization",
          "Outcomes": ""
        },
        {
          "Population": "intermediate stage hepatocellular carcinoma (i.e. BCLCB stage; i.e. large, multinodular, Child-Pugh status A to B, and performance status 0)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6111
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6111
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7016
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5552
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 29,
      "ContextTokens": 7389
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7346
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatocellular carcinoma for whom intentional curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically unnecessary (advanced hepatocellulose cancer)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 4583
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [],
      "ChunksUsed": 30,
      "ContextTokens": 6985
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 22,
      "ContextTokens": 3364
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": ""
        },
        {
          "Population": "patients with HCC with non-viral etiologies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6717
    }
  }
}